US6878206B2
(en)
|
2001-07-16 |
2005-04-12 |
Applied Materials, Inc. |
Lid assembly for a processing system to facilitate sequential deposition techniques
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
MXPA05001096A
(es)
|
2002-07-29 |
2005-11-23 |
Rigel Pharmaceuticals Inc |
Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
|
KR20120062863A
(ko)
|
2003-07-30 |
2012-06-14 |
리겔 파마슈티칼스, 인크. |
자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
|
JP4808628B2
(ja)
*
|
2003-12-03 |
2011-11-02 |
ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド |
アゾール系キナーゼ阻害剤
|
AU2005252160A1
(en)
|
2004-04-13 |
2005-12-22 |
Astellas Pharma Inc. |
Polycyclic pyrazines as potassium ion channel modulators
|
US7884109B2
(en)
|
2005-04-05 |
2011-02-08 |
Wyeth Llc |
Purine and imidazopyridine derivatives for immunosuppression
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
KR20080034483A
(ko)
*
|
2005-07-26 |
2008-04-21 |
버텍스 파마슈티칼스 인코포레이티드 |
단백질 키나제의 억제제로서 유용한 벤즈이미다졸
|
EP3332807B1
(en)
|
2005-10-26 |
2023-02-22 |
Novartis AG |
Use of anti il-1beta antibodies
|
KR20080071600A
(ko)
|
2005-11-21 |
2008-08-04 |
노파르티스 아게 |
Mtor 억제제를 사용하는 신경내분비 종양 치료법
|
GB0601744D0
(en)
|
2006-01-27 |
2006-03-08 |
Novartis Ag |
Organic compounds
|
US7989459B2
(en)
*
|
2006-02-17 |
2011-08-02 |
Pharmacopeia, Llc |
Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
|
US8962643B2
(en)
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
WO2007109362A2
(en)
|
2006-03-20 |
2007-09-27 |
Synta Pharmaceuticals Corp. |
Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
|
US8163777B2
(en)
*
|
2006-03-23 |
2012-04-24 |
Synta Pharmaceuticals Corp. |
Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
|
WO2008043019A1
(en)
|
2006-10-04 |
2008-04-10 |
Pharmacopeia, Inc |
8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
|
US7902187B2
(en)
*
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
US7919490B2
(en)
*
|
2006-10-04 |
2011-04-05 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
CA2673125C
(en)
|
2006-10-19 |
2015-04-21 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
EP2099774A4
(en)
*
|
2006-11-15 |
2010-11-24 |
Ym Biosciences Australia Pty L |
INHIBITORS OF KINASEACTIVITY
|
AU2013273769B2
(en)
*
|
2006-11-15 |
2016-05-12 |
Ym Biosciences Australia Pty Ltd |
Inhibitors of Kinase Activity
|
JP2010510211A
(ja)
*
|
2006-11-16 |
2010-04-02 |
ファーマコペイア・リミテッド・ライアビリティ・カンパニー |
免疫抑制用7−置換プリン誘導体
|
US20080119496A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Pharmacopeia Drug Discovery, Inc. |
7-Substituted Purine Derivatives for Immunosuppression
|
CA3080328C
(en)
|
2007-05-29 |
2022-06-21 |
Novartis Ag |
New indications for anti-il-1-beta therapy
|
TWI444379B
(zh)
|
2007-06-29 |
2014-07-11 |
Sunesis Pharmaceuticals Inc |
有用於作為Raf激酶抑制劑之化合物
|
CA2694284A1
(en)
|
2007-06-29 |
2009-01-08 |
Jennifer Cossrow |
Heterocyclic compounds useful as raf kinase inhibitors
|
WO2009037247A1
(en)
*
|
2007-09-17 |
2009-03-26 |
Neurosearch A/S |
Pyrazine derivatives and their use as potassium channel modulators
|
AU2008314632B2
(en)
|
2007-10-19 |
2015-05-28 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US7989465B2
(en)
*
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
US20100233716A1
(en)
|
2007-11-08 |
2010-09-16 |
Pierre Saint-Mezard |
Transplant rejection markers
|
EP2252618A1
(en)
*
|
2007-12-19 |
2010-11-24 |
Vertex Pharmaceuticals Incorporated |
PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
WO2009136995A2
(en)
|
2008-04-16 |
2009-11-12 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk protein kinase
|
PT2323993E
(pt)
|
2008-04-16 |
2015-10-12 |
Portola Pharm Inc |
2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
CN103224497A
(zh)
|
2008-04-22 |
2013-07-31 |
波托拉医药品公司 |
蛋白激酶抑制剂
|
US20090275529A1
(en)
*
|
2008-05-05 |
2009-11-05 |
Reiss Allison B |
Method for improving cardiovascular risk profile of cox inhibitors
|
BRPI0909945A2
(pt)
|
2008-06-20 |
2015-07-28 |
Genentech Inc |
"composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
|
RU2560153C2
(ru)
|
2008-06-20 |
2015-08-20 |
Дженентек, Инк. |
Триазолпиридиновые соединения, ингибирующие jak, и способы
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
EP3549934A1
(en)
|
2008-06-27 |
2019-10-09 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Egfr 억제제 및 질환 치료방법
|
CA2767616A1
(en)
|
2009-07-09 |
2011-01-13 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
JP2013525392A
(ja)
*
|
2010-04-30 |
2013-06-20 |
セルゾーム リミティッド |
Jak阻害剤としてのピラゾール化合物
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
BR112013003388A2
(pt)
|
2010-08-10 |
2016-07-12 |
Celgene Avilomics Res Inc |
sal de besilato de um inibidor de btk
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
US20130317029A1
(en)
|
2010-11-01 |
2013-11-28 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
JP5957460B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
複素環式化合物またはその使用
|
US8846928B2
(en)
|
2010-11-01 |
2014-09-30 |
Portola Pharmaceuticals, Inc. |
Benzamides and nicotinamides as Syk modulators
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
US8796255B2
(en)
|
2010-11-10 |
2014-08-05 |
Celgene Avilomics Research, Inc |
Mutant-selective EGFR inhibitors and uses thereof
|
US8889684B2
(en)
*
|
2011-02-02 |
2014-11-18 |
Boehringer Ingelheim International Gmbh |
Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
|
SG193982A1
(en)
|
2011-03-28 |
2013-11-29 |
Mei Pharma Inc |
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
EP2710006A1
(en)
|
2011-05-17 |
2014-03-26 |
Principia Biopharma Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
CN102267980B
(zh)
*
|
2011-06-04 |
2012-11-21 |
山西大学 |
2,6-二苯并咪唑基吡啶的制备方法
|
CA2840315A1
(en)
|
2011-06-27 |
2013-01-03 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
CA2841111A1
(en)
|
2011-07-08 |
2013-01-17 |
Novartis Ag |
Novel pyrrolo pyrimidine derivatives
|
CN103987699A
(zh)
|
2011-10-21 |
2014-08-13 |
诺华股份有限公司 |
作为pi3k调节剂的喹唑啉衍生物
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
AU2012340555B2
(en)
|
2011-11-23 |
2016-10-20 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
AP2014007680A0
(en)
|
2011-12-02 |
2014-06-30 |
Novartis Ag |
Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
|
EA029473B1
(ru)
|
2011-12-15 |
2018-03-30 |
Новартис Аг |
Применение ингибиторов pi3k для лечения острой и церебральной малярии
|
US20150148377A1
(en)
|
2011-12-22 |
2015-05-28 |
Novartis Ag |
Quinoline Derivatives
|
PL2794600T3
(pl)
|
2011-12-22 |
2018-06-29 |
Novartis Ag |
Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
|
US9464089B2
(en)
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
EP2802568A1
(en)
|
2012-01-13 |
2014-11-19 |
Acea Biosciences, Inc. |
Heterocyclic compounds and uses as anticancer agents.
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
WO2013138495A1
(en)
|
2012-03-15 |
2013-09-19 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
CN104284584B
(zh)
|
2012-03-15 |
2019-06-04 |
西建卡尔有限责任公司 |
表皮生长因子受体激酶抑制剂的盐
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
MX2015001081A
(es)
|
2012-07-24 |
2015-10-14 |
Pharmacyclics Inc |
Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
|
US9573958B2
(en)
|
2012-08-31 |
2017-02-21 |
Principia Biopharma, Inc. |
Benzimidazole derivatives as ITK inhibitors
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
JP6412503B2
(ja)
|
2012-11-21 |
2018-10-24 |
ピーティーシー セラピューティクス, インコーポレイテッド |
置換逆ピリミジンBmi−1阻害剤
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
DK3007689T3
(en)
|
2013-01-10 |
2018-06-14 |
Pulmokine Inc |
NON-SELECTIVE KINASE INHIBITORS
|
BR112015017331B1
(pt)
|
2013-01-23 |
2022-01-11 |
Astrazeneca Ab |
Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição
|
US9145387B2
(en)
|
2013-02-08 |
2015-09-29 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
NZ715687A
(en)
|
2013-07-11 |
2019-04-26 |
Acea Biosciences Inc |
Pyrimidine derivatives as kinase inhibitors
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
TWI692477B
(zh)
|
2013-08-30 |
2020-05-01 |
美商Ptc治療公司 |
經取代嘧啶bmi-1抑制劑
|
KR20160060100A
(ko)
|
2013-09-22 |
2016-05-27 |
칼리토르 사이언시즈, 엘엘씨 |
치환된 아미노피리미딘 화합물 및 이용 방법
|
ES2959419T3
(es)
|
2013-10-11 |
2024-02-26 |
Pulmokine Inc |
Formulaciones secas por aspersión
|
EP3071553A4
(en)
*
|
2013-11-21 |
2017-08-02 |
PTC Therapeutics, Inc. |
Substituted pyridine and pyrazine bmi-1 inhibitors
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
PT3134396T
(pt)
|
2014-04-24 |
2019-12-16 |
Novartis Ag |
Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
|
KR20160141856A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
|
CN106458979B
(zh)
|
2014-04-24 |
2020-03-27 |
诺华股份有限公司 |
作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
EP3825417A3
(en)
|
2014-05-22 |
2021-09-15 |
The Scripps Research Institute |
Tissue molecular signatures of kidney transplant rejections
|
EP3179858B1
(en)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Forms and compositions of an erk inhibitor
|
TWI679205B
(zh)
|
2014-09-02 |
2019-12-11 |
日商日本新藥股份有限公司 |
吡唑并噻唑化合物及醫藥
|
GB201518456D0
(en)
*
|
2015-10-19 |
2015-12-02 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
|
TWI712604B
(zh)
|
2016-03-01 |
2020-12-11 |
日商日本新藥股份有限公司 |
具jak抑制作用之化合物之結晶
|
CA3026784A1
(en)
|
2016-06-07 |
2017-12-14 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic pyrazine derivatives useful as shp2 inhibitors
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
WO2018081567A1
(en)
|
2016-10-27 |
2018-05-03 |
Pulmokine, Inc. |
Combination therapy for treating pulmonary hypertension
|
KR20210130254A
(ko)
|
2017-03-23 |
2021-10-29 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
US11498922B2
(en)
|
2017-04-07 |
2022-11-15 |
ACEA Therapeutics, Inc. |
Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
|
MX2019013862A
(es)
|
2017-05-23 |
2020-01-20 |
Mei Pharma Inc |
Terapia de combinacion.
|
BR112020002984A2
(pt)
|
2017-08-14 |
2020-08-11 |
Mei Pharma, Inc. |
terapia combinada
|
US10793551B2
(en)
|
2017-10-19 |
2020-10-06 |
Effector Therapeutics Inc. |
Benzimidazole-indole inhibitors of Mnk1 and Mnk2
|
JP2021500394A
(ja)
|
2017-10-27 |
2021-01-07 |
シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド |
αタンパク質キナーゼ1を活性化することによって免疫応答をモジュレートするための組成物および方法
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
WO2020212395A1
(en)
|
2019-04-16 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
KR20220012280A
(ko)
|
2019-05-23 |
2022-02-03 |
노파르티스 아게 |
Btk 저해제의 결정질 형태
|
CN112358468B
(zh)
*
|
2020-11-10 |
2022-03-22 |
德州德药制药有限公司 |
一种工业化合成azd9291的方法
|
CN112980809B
(zh)
*
|
2021-03-17 |
2023-04-11 |
云南中烟工业有限责任公司 |
一种烟草法尼基焦磷酸合酶基因及其应用
|
WO2023083330A1
(zh)
*
|
2021-11-12 |
2023-05-19 |
百极优棠(广东)医药科技有限公司 |
Drak2抑制剂及其制备方法和应用
|
WO2023222565A1
(en)
|
2022-05-16 |
2023-11-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
|